CFA
AKBA icon

Camarda Financial Advisors’s Akebia Therapeutics AKBA Stock Holding History

Camarda Financial Advisors’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-2,000
Closed -$15K – 210
2016
Q2 		$15K Hold
2,000
– – 0.01% 191
2016
Q1 		$18K Buy
+2,000
New +$16.2K 0.01% 169

Other funds holding AKBA

EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

Camarda Financial Advisors's AKBA Position: Q3 2016 in Review

Camarda Financial Advisors sold out of Akebia Therapeutics (AKBA) in Q3 2016, closing a stake of 2,000 shares — an estimated $15K sold.

Camarda Financial Advisors first reported a position in AKBA in Q1 2016 and held it in 2 quarters. The position peaked at $18K in Q1 2016. 86 funds tracked by Wall St. Rank hold AKBA as of Q3 2016.

  • Camarda Financial Advisors reported no remaining Akebia Therapeutics position as of Q3 2016 after selling out during the quarter.
  • Camarda Financial Advisors sold 2,000 Akebia Therapeutics shares in Q3 2016, an estimated $15K.
  • Camarda Financial Advisors first reported a position in Akebia Therapeutics in Q1 2016 and held it in 2 quarters.
  • Camarda Financial Advisors's Akebia Therapeutics position peaked at $18K in Q1 2016.
  • 86 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2016.

Based on Camarda Financial Advisors's 13F filing for Q3 2016, filed 10 Nov 2016.